ISRG Research Note: The business is not the question, the price is

The ISRG research family (page counts are those of the approved PDF editions, which this site does not host):

• Deep Dive: A franchise worth owning at a price that asks for more than we can find (47 pages). Public preview; the Deep Dive page says how to read the full report.
• Research Note: The business is not the question, the price is (5 pages).
• Technical Appendix: The model behind the rating, in figures (14 pages).
• Learning Companion: How to read the Intuitive Surgical research (12 pages).

---

The judgment

Intuitive is one of the best businesses we cover, and we rate its shares 1 / 5 POOR anyway. The company earns most of its revenue each time a surgeon uses a da Vinci or Ion system, it reported $8.71 billion of revenue in the first nine months of 2026 (up 21.0%), and it holds $6.80 billion of cash and investments with no borrowings. At the 11-02-2026 close of $436.87 the market value was $151.4 billion, 55.5 times last year's earnings per share, and our work says the cash flows we can defend are worth between $118.22 and $268.49 per share, with $193.46 on our reference path. The price is above all three.

Since the valuation date

The close was $460.56 on 11-09-2026, the November 9, 2026 regular-session closing price and the latest settled close in our data, 5.4% above the $436.87 of the valuation date. Our values are those of 11-02-2026 and have not been rolled forward or recalculated, so the downside, reference and upside values are now 74.3%, 58.0% and 41.7% below the latest close, against 72.9%, 55.7% and 38.5% below at the valuation date. Solved again at the new close, the reference cash flows equal the price only at a discount rate of 6.35%, against 6.48% at the valuation date, or with da Vinci growth 15.0 points higher in every year from 2027 to 2035, against 14.1 points. The Treasury table we hold ends at 11-06-2026, when the ten-year par yield was 4.86% against 4.91% at the valuation date. The list of SEC filings we hold, retrieved on 11-07-2026, shows only insider filings from Intuitive since our earlier evidence date, and we did not repeat that check for the new close, so there is no new operating evidence. The comparison does not change our reading: the rating stays 1 / 5 POOR at the 11-02-2026 close of $436.87. Unless a sentence names another date, "the close" below is that 11-02-2026 close.

What eight years of reporting show

The record is strong, and the per-procedure figure ended close to where it began. From FY2018 to FY2025 revenue compounded at 15.3% a year, instruments and accessories revenue at 17.4%, and the installed base of da Vinci systems at 12.1%, while procedures per average system rose from 233 in FY2019 to 300 in FY2025. Instruments and accessories revenue per da Vinci procedure, which is our own ratio and not a company figure, was $1,890 in FY2018 and $1,909 in FY2025, only 1.0% higher, so over the whole record growth came from volume and from a larger base, not from a rising price per procedure. The years between were not flat: after the extended-use program and the price cuts that came with it in late 2020, a program the company said would lower its revenue per procedure, the figure fell 5.3% from FY2020 to FY2023 and then recovered 2.0% by FY2025. The planned reset is therefore not the first company-announced cut in the record we read, and it matters because it lands while U.S. growth is slowing. The record is also less smooth than the average suggests. Revenue growth was -2.7% in FY2020 and 9.0% in FY2022, adjusted operating margin ranged from 25.1% to 32.6%, and a leased-system model turned fast placements into investment before revenue, so that operating cash flow less purchases fell to 41.7% of net income in FY2023, when gross investment reached 20.9% of revenue, and recovered to 87.2% in FY2025.

The evidence that decides it

Three facts carry the argument. US da Vinci procedure growth slowed from approximately 12% in the second quarter to approximately 10% in the third, while worldwide growth was 13.7% in the third quarter and growth outside the United States approximately 20%. Management expects its announced pricing actions to cut da Vinci instruments and accessories revenue per procedure by about 3% to 5% once fully implemented, starting in China in the fourth quarter of 2026, in response to a national pricing framework set by the regulator there, and continuing with extended-use and volume-based pricing in the first half of 2027; that is a management claim about its own plan, and whether more procedures follow is unproven. And the repricing lands on the instruments and accessories line, 59.9% of revenue in the first nine months of 2026; the guidance speaks to the da Vinci part of that line, which also carries Ion's instruments. None of this makes the business weak. It makes a price built on a mid-teens growth path hard to support, because a point or two of growth lost early compounds through a ten-year forecast and through a terminal value that is 63.2% of the reference enterprise value.

We read earnings conservatively: share-based pay stays in as a cost, systems leased to hospitals are counted as investment, and we use a 22% tax rate, not the 13.1% to 18.4% the company has reported, because the reported rates are lowered by benefits that move with the share price. The 2026 margin of 33.4% includes $63.7 million of tariff refunds; without them it is 32.7%.

Where the price sits against our values

Our values are conditional paths at 11-02-2026, unweighted and not forecasts. The downside ($118.22, 27.1% of the 11-02-2026 close) is an enduring impairment, the reference ($193.46, 44.3%) is our best-supported central path, and the upside ($268.49, 61.5%) has the past decade's pattern continuing with a slow fade. Holding the rest of the reference fixed, that close is reached at a discount rate of 6.48% (we use 9.91%), or with da Vinci growth 14.1 points higher in every year from 2027 to 2035. Moving both inputs together does not rescue it: even at a discount rate of 7.91%, two points below ours, growth would have to run 7.0 points above the reference in every year. Stacking the favorable end of each of the eight judgments our independent challenge tested gives $358.94, which is 82.2% of that close; it keeps the announced price cut, volume response, mix and erosion at the reference, and we regard it as a stress and not a case. The discount rate is the largest single lever and rests on two judgments, beta and the equity risk premium, that we have not measured; one point either way takes the reference to $229.53 or $167.78.

Two checks built a different way point the same direction. Capitalizing today's earnings with no growth gives $105.31 per share, 24.1% of the close, so the price is mostly a payment for growth. And the reference's return on new capital in its first terminal year, 24.2%, sits inside the 23.0% to 25.9% the business earned on its invested capital in FY2023 to FY2025, so the reference does not lean on returns the recent record cannot support, even though the same measure ran from 43.3% to 51.1% in FY2018, FY2019 and FY2021, when far less capital was employed. The terminal value on the reference is 11.5 times 2035 adjusted operating profit, against the 37.4 times annualized adjusted operating profit, tariff refunds included, at which the market valued the company at the close, or 38.2 times without them.

Three things are easy to run together here. The values are what our model computes at the 11-02-2026 valuation date, from an explicit forecast to 2035 with a terminal value. The rating weighs the price against those values and the evidence. How the shares perform over the next twelve months is a third question, and this research does not forecast it: the gap between the close and our values is measured at the valuation date, and whether or when it narrows is not something we predict.

The strongest counterargument

The best case against us is Intuitive's own record. It has grown procedures at 17.1% a year from FY2018 to FY2024 and grew through its last price cut, after which revenue per procedure fell 5.3% and then recovered, and in our judgment, which we hold no valuation history to test, the market has paid more than discounted cash flows of this kind for much of that time. A ten-year forecast may also cut off a long runway in benign procedures and outside the United States, where procedures grew approximately 20% in the third quarter of 2026, that the 2027 pricing is meant to open. A company with $6.8 billion of cash and a recurring model might deserve a lower cost of capital than ours. Our upside path gives that case its best honest form, with growth fading from 14.5% to 7.5% and a margin near 37%, and it is worth $268.49. The case on the other side is that the downside, at $118.22, still keeps a 14.0% return on new capital, well below what the business has earned but still above the cost of capital, so it stops short of a collapse in returns; that Medtronic's Hugo now has FDA clearance in urology, with general surgery and gynecology in Medtronic's U.S. pipeline, while Medtronic has invested approximately $700 million in Cornerstone with rights to its system outside the United States; that Intuitive itself says domestic competition in China has cost it system placements; and that two antitrust suits besides the class action settlement awaiting approval remain open with no estimate of loss. We keep both cases in view and we would not be surprised to be wrong about the speed of the slowdown, but we cannot build the price from any combination we find supportable.

What would change our view

Evidence that US growth is stabilizing rather than falling, a volume response to the new instrument pricing strong enough to hold revenue growth near 14% for several years, or a better-measured required return would raise our values. Further falls in US growth, price erosion beyond the announced actions, a US indication that makes a rival robot a real alternative in the high-volume procedures, or a harsher outcome for the $450 million antitrust settlement would lower them. A price much closer to our reference value would also change the rating, with the business unchanged: a 2 / 5 reading would need a close near our upside value, which is a close 38.5% lower than the one we assessed and 41.7% lower than the 11-09-2026 settled close, and a 3 / 5 reading a close near our reference, 55.7% lower than the one we assessed and 58.0% lower than the 11-09-2026 settled close. Items to watch: the fourth-quarter results (their date is not confirmed in our sources), the first-half 2027 pricing changes as the company describes its plan, and court approval of the settlement.

Assumptions and disclosure

The Blockhaven Rating is Blockhaven's own five-level assessment at a stated price and horizon; it is not individualized advice or a recommendation to trade. Values are conditional model outputs, not price targets.

Important disclosures

Blockhaven research is provided for general informational and educational purposes. It is not individualized investment advice and does not take into account any reader's financial circumstances, investment objectives, risk tolerance, tax situation or portfolio.

Nothing in this report is an offer or a solicitation to buy or sell a security or other financial instrument. Reading or accessing Blockhaven research does not by itself create an investment-advisory, fiduciary, brokerage or client relationship.

Investing involves risk, including the possible loss of principal. Scenario values, terminal values, valuation ranges, sensitivities and forward-looking assumptions are analytical tools, not guarantees or promises of future performance, and actual results may differ materially.

Blockhaven uses information from company filings, company publications, market-data providers and other sources it believes to be reliable, but that information may be incomplete, delayed, revised or incorrect.

Opinions, ratings and interpretations reflect Blockhaven's research judgment as of the report date and may change as new evidence becomes available.

Positions and conflicts

As of November 6, 2026, Blockhaven's owner held no shares, options, or other direct derivatives in Intuitive Surgical, Inc.; had no material positions in Intuitive Surgical, Inc. through entities the owner controls; and had no paid financial relationships with Intuitive Surgical, Inc.

© 2026 Blockhaven LLC. All rights reserved.